Skip to main content

Fresenius is a global healthcare group, comprised of the Operating Companies Fresenius Kabi and Fresenius Helios (each with 100% ownership share) and the Investment Companies Fresenius Medical Care and Fresenius Vamed1.  

Our Operating Companies put our focus on system-critical healthcare products and services for leading therapies into effect and are geared towards profitability optimization and growth. In line with the role of Fresenius as significant shareholder, our Investment Companies will be focused on financial value management.


Fresenius Kabi

Fresenius Kabi specializes in products for the therapy and care of critically and chronically ill patients. The portfolio includes biopharmaceuticals, clinical nutrition, MedTech products, intravenously administered generic drugs (generic IV drugs), and IV fluids. 

Fresenius Helios

Fresenius Helios stands for healthcare services and is Europe’s leading private hospital operator. The company includes Helios Germany and Quirónsalud. Helios Germany and Quirónsalud provides services to patients in its hospitals and healthcare centers in Germany, Spain, and Latin America.

Fresenius Medical Care

Fresenius Medical Care offers services and products for patients with chronic kidney failure. Dialyzers and dialysis machines are among the most important product lines. In addition, Fresenius Medical Care offers dialysis-related services.

Fresenius Vamed1

Fresenius Vamed internationally manages projects and provides services for hospitals and other health care facilities and is a leading post-acute care provider in Central Europe. The portfolio ranges along the entire value chain: from project development, design planning, medical and hospital engineering as well as construction, via maintenance and technical management to total operational management and high-end services.

1 Fresenius announced a structured exit from its Investment Company Vamed; as of Q2 2024, Vamed will no longer be a reporting segment of Fresenius.